It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PDRX’s FA Score shows that 0 FA rating(s) are green whileSHPMY’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PDRX’s TA Score shows that 3 TA indicator(s) are bullish while SHPMY’s TA Score has 4 bullish TA indicator(s).
PDRX (@Medical Distributors) experienced а +4.92% price change this week, while SHPMY (@Medical Distributors) price change was -0.12% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +0.86%. For the same industry, the average monthly price growth was +2.51%, and the average quarterly price growth was +147.05%.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
PDRX | SHPMY | PDRX / SHPMY | |
Capitalization | N/A | 9.5B | - |
EBITDA | N/A | 11.1B | - |
Gain YTD | -54.286 | 16.659 | -326% |
P/E Ratio | N/A | 8.39 | - |
Revenue | N/A | 241B | - |
Total Cash | N/A | N/A | - |
Total Debt | N/A | N/A | - |
PDRX | SHPMY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 44 Fair valued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 79 | |
SMR RATING 1..100 | 100 | 81 | |
PRICE GROWTH RATING 1..100 | 86 | 43 | |
P/E GROWTH RATING 1..100 | 100 | 36 | |
SEASONALITY SCORE 1..100 | n/a | 95 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SHPMY's Valuation (39) in the null industry is in the same range as PDRX (44). This means that SHPMY’s stock grew similarly to PDRX’s over the last 12 months.
SHPMY's Profit vs Risk Rating (79) in the null industry is in the same range as PDRX (100). This means that SHPMY’s stock grew similarly to PDRX’s over the last 12 months.
SHPMY's SMR Rating (81) in the null industry is in the same range as PDRX (100). This means that SHPMY’s stock grew similarly to PDRX’s over the last 12 months.
SHPMY's Price Growth Rating (43) in the null industry is somewhat better than the same rating for PDRX (86). This means that SHPMY’s stock grew somewhat faster than PDRX’s over the last 12 months.
SHPMY's P/E Growth Rating (36) in the null industry is somewhat better than the same rating for PDRX (100). This means that SHPMY’s stock grew somewhat faster than PDRX’s over the last 12 months.
PDRX | SHPMY | |
---|---|---|
RSI ODDS (%) | 4 days ago33% | N/A |
Stochastic ODDS (%) | 5 days ago43% | 4 days ago73% |
Momentum ODDS (%) | 4 days ago41% | 4 days ago54% |
MACD ODDS (%) | N/A | 4 days ago62% |
TrendWeek ODDS (%) | 4 days ago29% | 4 days ago63% |
TrendMonth ODDS (%) | 4 days ago31% | 4 days ago67% |
Advances ODDS (%) | N/A | 7 days ago59% |
Declines ODDS (%) | N/A | 18 days ago60% |
BollingerBands ODDS (%) | 4 days ago35% | 4 days ago66% |
Aroon ODDS (%) | N/A | 4 days ago63% |
A.I.dvisor tells us that PDRX and NSVGF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PDRX and NSVGF's prices will move in lockstep.
Ticker / NAME | Correlation To PDRX | 1D Price Change % | ||
---|---|---|---|---|
PDRX | 100% | N/A | ||
NSVGF - PDRX | 8% Poorly correlated | N/A | ||
MAHLY - PDRX | 2% Poorly correlated | N/A | ||
SHPMY - PDRX | 0% Poorly correlated | N/A | ||
ARRJF - PDRX | 0% Poorly correlated | N/A | ||
MEPDF - PDRX | 0% Poorly correlated | N/A | ||
More |
A.I.dvisor tells us that SHPMY and NSVGF have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPMY and NSVGF's prices will move in lockstep.
Ticker / NAME | Correlation To SHPMY | 1D Price Change % | ||
---|---|---|---|---|
SHPMY | 100% | N/A | ||
NSVGF - SHPMY | 14% Poorly correlated | N/A | ||
COSM - SHPMY | 12% Poorly correlated | -5.82% | ||
SHTDF - SHPMY | 12% Poorly correlated | -2.35% | ||
ZYXI - SHPMY | 7% Poorly correlated | -1.79% | ||
SHPMF - SHPMY | 7% Poorly correlated | N/A | ||
More |